EAM Investors’s Protara Therapeutics TARA Stock Holding History

EAM Investors’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-103,611	Closed	-$552K	–	369
2025 Q4	$552K	Buy	+103,611	New	+$576K	0.06%	253

Other funds holding TARA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

EAM Investors's TARA Position: Q1 2026 in Review

EAM Investors sold out of Protara Therapeutics (TARA) in Q1 2026, closing a stake of 103,611 shares — an estimated $552K sold.

EAM Investors first reported a position in TARA in Q4 2025 and held it in 1 quarter. The position peaked at $552K in Q4 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

EAM Investors reported no remaining Protara Therapeutics position as of Q1 2026 after selling out during the quarter.
EAM Investors sold 103,611 Protara Therapeutics shares in Q1 2026, an estimated $552K.
EAM Investors first reported a position in Protara Therapeutics in Q4 2025 and held it in 1 quarter.
EAM Investors's Protara Therapeutics position peaked at $552K in Q4 2025.
114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.